Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treprostinil palmitil - Insmed

Next Previous
Drug Profile

Treprostinil palmitil - Insmed

Alternative Names: C16-TR; INS-1009; Nebulised treprostinil palmitil - Insmed; Nebulised treprostinil prodrug - Insmed; TPIP; TPIS - Insmed; Treprostinil palmitil inhalation powder - Insmed; Treprostinil palmitil inhalation suspension - Insmed

Latest Information Update: 24 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Insmed
  • Class Acetic acids; Antifibrotics; Antihypertensives; Antineoplastics; Cyclopentanes; Heart failure therapies; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pulmonary hypertension
  • Phase II/III Pulmonary arterial hypertension
  • No development reported Idiopathic pulmonary fibrosis

Most Recent Events

  • 19 Feb 2026 Treprostinil palmitil - Insmed receives Orphan Drug status for Pulmonary arterial hypertension in USA
  • 15 Jan 2026 Phase-III clinical trials in Pulmonary hypertension in Japan, Israel (Inhalation) (NCT07179380)
  • 09 Jan 2026 Insmed plans to initiate a Phase III trial for pulmonary arterial hypertension (PAH), Progressive Pulmonary Fibrosis (PPF) and Idiopathic Pulmonary Fibrosis (IPF) in 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top